Mary Jane Sneyd1, Andrew R Gray2, Ian M Morison3. 1. Hugh Adam Cancer Epidemiology Unit, Department of Preventive and Social Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. mary-jane.sneyd@otago.ac.nz. 2. Biostatistics Centre, University of Otago, Dunedin, New Zealand. 3. Department of Pathology, University of Otago, Dunedin, New Zealand.
Abstract
BACKGROUND: Myeloma survival has greatly increased over past decades. We investigated trends in survival over time in New Zealand by age, ethnicity, and geography and thus examined potential inequalities among these population subgroups. METHODS: From data supplied by the New Zealand Ministry of Health, all new diagnoses of multiple myeloma (ICD-10 code C90) between 1990 and 2016 were extracted, as well as their matched mortality data. Cox's proportional hazards regression and competing risks regression were used to estimate multivariable survival functions. RESULTS: Between 1 January 1990 and 1 December 2015, 6642 myeloma cases were registered by the New Zealand Cancer Registry. Although survival from myeloma increased substantially from 1990-1994 to 2010-2015, 5-year survival was still only about 60% in 2010-2015. The greatest improvement in survival was for people aged 60-69 years at diagnosis. Using Cox's proportional hazards regression, Māori showed an increased risk of myeloma death but this was predominantly due to differences in competing risks among ethnic groups. Competing risks analysis found the greatest improvement in myeloma survival in Pacific Islanders, and in 2010-2015 Māori had better survival than other ethnicities. Myeloma survival improved significantly over time in all regional health authorities but in all time periods the Central and Southern regions had significantly poorer survival than the Midland region. CONCLUSIONS: Improvements in myeloma survival have been unequal across subgroups and regions in New Zealand. Detailed information about utilization of chemotherapeutic agents and transplantation in New Zealand is not available. This information, as well as more detailed hematological data, is essential to further explore the relationships and reasons for differing myeloma survival in population subgroups of New Zealand.
BACKGROUND:Myeloma survival has greatly increased over past decades. We investigated trends in survival over time in New Zealand by age, ethnicity, and geography and thus examined potential inequalities among these population subgroups. METHODS: From data supplied by the New Zealand Ministry of Health, all new diagnoses of multiple myeloma (ICD-10 code C90) between 1990 and 2016 were extracted, as well as their matched mortality data. Cox's proportional hazards regression and competing risks regression were used to estimate multivariable survival functions. RESULTS: Between 1 January 1990 and 1 December 2015, 6642 myeloma cases were registered by the New Zealand Cancer Registry. Although survival from myeloma increased substantially from 1990-1994 to 2010-2015, 5-year survival was still only about 60% in 2010-2015. The greatest improvement in survival was for people aged 60-69 years at diagnosis. Using Cox's proportional hazards regression, Māori showed an increased risk of myeloma death but this was predominantly due to differences in competing risks among ethnic groups. Competing risks analysis found the greatest improvement in myeloma survival in Pacific Islanders, and in 2010-2015 Māori had better survival than other ethnicities. Myeloma survival improved significantly over time in all regional health authorities but in all time periods the Central and Southern regions had significantly poorer survival than the Midland region. CONCLUSIONS: Improvements in myeloma survival have been unequal across subgroups and regions in New Zealand. Detailed information about utilization of chemotherapeutic agents and transplantation in New Zealand is not available. This information, as well as more detailed hematological data, is essential to further explore the relationships and reasons for differing myeloma survival in population subgroups of New Zealand.
Authors: M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille Journal: N Engl J Med Date: 1996-07-11 Impact factor: 91.245
Authors: Parameswaran N Hari; Navneet S Majhail; Mei-Jie Zhang; Anna Hassebroek; Fareeha Siddiqui; Karen Ballen; Asad Bashey; Jenny Bird; Cesar O Freytes; John Gibson; Gregaory Hale; Leona Holmberg; Ram Kamble; Robert A Kyle; Hillard M Lazarus; Charles F LeMaistre; Fausto Loberiza; Angelo Maiolino; Philip L McCarthy; Gustavo Milone; Nancy Omondi; Donna E Reece; Matthew Seftel; Michael Trigg; David Vesole; Brendan Weiss; Peter Wiernik; Stephanie J Lee; J Douglas Rizzo; Paulette Mehta Journal: Biol Blood Marrow Transplant Date: 2009-11-14 Impact factor: 5.742
Authors: Shaji Kumar; Lawrence Baizer; Natalie S Callander; Sergio A Giralt; Jens Hillengass; Boris Freidlin; Antje Hoering; Paul G Richardson; Elena I Schwartz; Anthony Reiman; Suzanne Lentzsch; Philip L McCarthy; Sundar Jagannath; Andrew J Yee; Richard F Little; Noopur S Raje Journal: Blood Cancer J Date: 2022-06-29 Impact factor: 9.812